Navigation Links
Stryker Presents Results of the TREVO Prospective Clinical Study at the International Stroke Conference
Date:2/2/2012

KALAMAZOO, Mich., Feb. 2, 2012 /PRNewswire/ -- On February 2, at the Late-Breaking Science Session at the International Stroke Conference, Stryker announced the results of the TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke). This was one of the first prospective, multi-center clinical studies of clot-removing stent retriever technology. Sixty patients were enrolled by seven leading stroke centers in Europe.

(Logo:  http://photos.prnewswire.com/prnh/20120202/NY46927LOGO )

The TREVO Study was designed to assess the ability of the Trevo® System to remove the blood clots that cause strokes and to restore blood flow to the brain. Revascularization was measured by an independent core lab.

The results were presented at the International Stroke Conference in New Orleans, LA by Professor Nils Wahlgren, co-Principal Investigator of the Study and Professor of Neurology at Karolinska University Hospital, Solna, Sweden. The results demonstrated high revascularization rates of 91.7% of patients. 46% of patients achieved a good outcome in just seven days and at 90 days, the good outcomes rate increased to 55%. These patients with good outcomes were functionally independent (modified Rankin score of 2 or less). A low symptomatic intracranial hemorrhage rate of 5% was also reported.

Professor Wahlgren commented: "The TREVO Study represents an important step forward in the evidence supporting the treatment of patients with moderate and severe strokes with mechanical thrombectomy devices, such as the Trevo System. The rigorous conduct of this prospective multicenter trial provides more confidence not only in patient selection, but in the successful procedural and clinical outcomes that can be achieved for these patients."

Clinical evidence remains key for wider adoption of interventional, device-based therapies for the treatment of Acute Ischemic Stroke. The prospective design and rigorous conduct of the TREVO Study underscores Stryker's commitment to building robust evidence to support the adoption of important technologies like the Trevo System by physicians for their stroke patients.

About Stryker

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit www.stryker.com.

Media Contact:
Tamara Cutler
Vice President, Public Affairs
269-389-7253
tamara.cutler@stryker.com


'/>"/>
SOURCE Stryker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. STRYKER Signs Definitive Agreement to Acquire CONCENTRIC MEDICAL, Inc.
2. Stryker Orthopaedics Enters into Agreement with OrthoSensor for Intelligent Surgical Platform
3. Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms
4. Stryker Ends Distribution Agreement With Corin PLC
5. Stryker Announces Exclusive Collaboration With RegenLab
6. Stryker Launches VersiTomic G-Lok™
7. Stryker Orthopaedics Launches Its First iPad™ Apps for Surgeons, Available Through Apples App Store(SM)
8. Stryker Features Tissue-Preservation Hip Arthroscopy Platform, Sponsors Surgeon Education Events at the AAOS Annual Meeting
9. Fred Funk Becomes Spokesperson for Stryker Orthopaedics
10. Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System
11. Stryker Declares a $0.18 Per Share Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
(Date:2/11/2016)... 2016   Health 2.0 , the premiere showcase ... announced today " 10 Year Global Retrospective ", a ... the past ten years.   --> ... 2.0 has served as the preeminent thought-leader in the ... of technologies, companies, innovators, and patient-activists through an array ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... With FCPX Overlay Embers from Pixel Film ... Final Cut Pro X. Each user can select from up to 40 effect overlays. ... blur, focus offset, hue, saturation, value, contrast, glow, and more all within a click ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, Inc. presented ... a VeinViewer® Vision vein finder for the nursing school simulation lab. ... and draw blood, combining technology with traditional technique. , “VeinViewer is a wonderful ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... Opelousas, LA (PRWEB) , ... February 12, 2016 , ... ... of St. Landry and Evangeline Parishes. The purpose of these scholarships is to ... to encourage those individuals to seek employment within these two parishes. , “We ...
(Date:2/12/2016)... ... 2016 , ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — ... Churchill said, “Those who don’t learn from history are doomed to repeat it.” , An ... knocking this year. But that takes time. , Take a close look at the ...
Breaking Medicine News(10 mins):